Monte Rosa Therapeutics Inc Revenue Growth Rates (GLUE), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Monte Rosa Therapeutics Inc   (NASDAQ: GLUE)
 

GLUE's Revenue Growth by Quarter and Year

Monte Rosa Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/GLUE/growth
https://api.csimarket.com/api/v1/companies/GLUE/fundamentals
https://api.csimarket.com/api/v1/companies/GLUE/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
GLUE Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 54.37
2nd Quarter June 8.97
1st Quarter March 4.21
FY 67.55





GLUE Revenue third quarter 2026 Y/Y Growth Comment
Monte Rosa Therapeutics Inc reported Revenue surge of 325.73% year on year in the third quarter 2026, to $ 54.37 millions, this is lower than Monte Rosa Therapeutics Inc 's recent average Revenue surge of 1343.8%.

Looking into third quarter 2026 results within Biotechnology & Pharmaceuticals industry 62 other companies have achieved higher Revenue growth. While Monte Rosa Therapeutics Inc ' s Revenue doubling of 325.73% ranks overall at the positon no. 3823 in the third quarter 2026.


GLUE Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 325.73 %
2nd Quarter June -61.32 %
1st Quarter March -95.04 %
FY   -

Financial Statements
Monte Rosa Therapeutics Inc 's third quarter 2026 Revenue $ 54.37 millions GLUE's Income Statement
Monte Rosa Therapeutics Inc 's third quarter 2025 Revenue $ 12.77 millions Quarterly GLUE's Income Statement


GLUE Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 506.09 %
2nd Quarter June 113.06 %
1st Quarter March 51.44 %
FY (Year on Year)   -


Back to GLUE Growth rate Comparisons >> Back to GLUE Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #63
Healthcare Sector #536
Overall #3823

Revenue Y/Y Growth Statistics
High Average Low
7882.05 % 1343.8 % -95.41 %
(Dec 31 2025)   (Jun 30 2026)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #63
Healthcare Sector #536
Overall #3823
Revenue Y/Y Growth Statistics
High Average Low
7882.05 % 1343.8 % -95.41 %
(Dec 31 2025)   (Jun 30 2026)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Monte Rosa Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
558.06 % 111.58 % -78.22 %
(Dec 31 2024)  


GLUE's III. Quarter Q/Q Revenue Comment
Monte Rosa Therapeutics Inc achieved in the III. Quarter 2026 above company average sequential Revenue doubling of 506.09%, to $ 54.37 millions, from $8.97 millions in the second quarter.
GLUE is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Biotechnology & Pharmaceuticals industry 4 other companies have achieved higher Revenue quarter on quarter growth. While Monte Rosa Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 126.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #5
Healthcare Sector #42
Overall #126
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #5
Healthcare Sector #42
Overall #126
Revenue Q/Q Growth Statistics
High Average Low
558.06 % 111.58 % -78.22 %
(Dec 31 2024)  


GLUE's III. Quarter Q/Q Revenue Comment
Monte Rosa Therapeutics Inc achieved in the III. Quarter 2026 above company average sequential Revenue doubling of 506.09%, to $ 54.37 millions, from $8.97 millions in the second quarter.
GLUE is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Biotechnology & Pharmaceuticals industry 4 other companies have achieved higher Revenue quarter on quarter growth. While Monte Rosa Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 126.


Monte Rosa Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 70.33
Y / Y Revenue Growth (TTM) -61.26 %
Year on Year Revenue Growth Overall Ranking # 274
Seqeuential Revenue Change (TTM) 144.8 %
Seq. Revenue Growth (TTM) Overall Ranking # 1350


Cumulative Revenue growth Comment
Monte Rosa Therapeutics Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Jun 30 2026. If the fiscal year would end in Sep 30 2026, Monte Rosa Therapeutics Inc 's annual Revenue surge would be -61.26% year on year to $70 millions.

In the Healthcare sector 71 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 101 to 274.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 30
Healthcare Sector # 72
Overall # 274

Revenue TTM Y/Y Growth Statistics
High Average Low
63.54 %
 -31.13 %
-83.86 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 30
Sector # 232
S&P 500 # 1350
Cumulative Revenue growth Comment
Monte Rosa Therapeutics Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Jun 30 2026. If the fiscal year would end in Sep 30 2026, Monte Rosa Therapeutics Inc 's annual Revenue drop would be -61.26% year on year to $70 millions.

In the Healthcare sector 71 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 101 to 274.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 30
Healthcare Sector # 72
Overall # 274

Revenue TTM Y/Y Growth Statistics
High Average Low
63.54 %
-31.13 %
-83.86 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 30
Sector # 232
S&P 500 # 1350




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
GLUE's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Bio Green Med Solution Inc 460.49%$ 460.494 millions
Xencor Inc454.88%$ 454.884 millions
Tonix Pharmaceuticals Holding Corp 423.83%$ 423.830 millions
Nakamoto Inc 396.90%$ 396.897 millions
EBR Systems, Inc.385.65%$ 385.647 millions
Solana Company382.07%$ 382.066 millions
Pulse Biosciences Inc 359.30%$ 359.302 millions
Ensysce Biosciences Inc 342.43%$ 342.428 millions
Nexalin Technology Inc 331.43%$ 331.434 millions
Agios Pharmaceuticals Inc 330.01%$ 330.008 millions
Insmed Inc330.00%$ 330.000 millions
Monte Rosa Therapeutics Inc 325.80%$ 325.799 millions
Liquidia Corporation314.60%$ 314.596 millions
Stablecoin Development Corporation310.75%$ 310.749 millions
Renovorx Inc 300.75%$ 300.752 millions
Aligos Therapeutics Inc 281.92%$ 281.916 millions
Clene Inc 273.33%$ 273.333 millions
Recursion Pharmaceuticals Inc 258.49%$ 258.493 millions
Nuvation Bio Inc 251.98%$ 251.977 millions
Seastar Medical Holding Corp246.99%$ 246.995 millions
Prime Medicine Inc 243.92%$ 243.918 millions
Urogen Pharma Ltd 227.16%$ 227.161 millions
Dianthus Therapeutics Inc 205.56%$ 205.556 millions
Bridgebio Pharma Inc 192.60%$ 192.602 millions
Bicycle Therapeutics Plc190.24%$ 190.242 millions
Gossamer Bio Inc 189.09%$ 189.085 millions
Alpha Cognition Inc.173.75%$ 173.751 millions
Eton Pharmaceuticals Inc 165.04%$ 165.042 millions


About Monte Rosa Therapeutics Inc Revenue Growth Rates (GLUE), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Monte Rosa Therapeutics Inc (CIK 1826457).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-448568
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Monte Rosa Therapeutics Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.